Impact of age, sex, and comorbidity on cancer therapy and disease progression - PubMed (original) (raw)

Review

. 2010 Sep 10;28(26):4086-93.

doi: 10.1200/JCO.2009.27.0579. Epub 2010 Jul 19.

Affiliations

• PMID: 20644100
• DOI: 10.1200/JCO.2009.27.0579

Review

Impact of age, sex, and comorbidity on cancer therapy and disease progression

Sumanta Kumar Pal et al. J Clin Oncol. 2010.

Abstract

A theme of personalized medicine was highlighted at the 2009 Annual Meeting of the American Society of Clinical Oncology. To this end, the current review focuses on the impact of host characteristics (such as age, sex, and comorbidity) as they pertain to cancer biology, treatment efficacy, and tolerance. Increasing age is associated with complex changes in physiology, including alterations in renal and hepatic function, and decreased bone marrow reserve. These may in turn result in alterations in pharmacokinetics and toxicity related to many commonly used anticancer agents. Using tools, such as the geriatric assessment, may help to elucidate the physiologic age of the patient as opposed to the chronologic age. Increasing age is paralleled by an increase in comorbidity, and comorbidity may have independent prognostic implications and substantially impact medical decision making in the patient with cancer. Numerous biologic ties between cancer and comorbidity exist, one example being an association of diabetes with an increased risk of disease recurrence and mortality in the setting of colon cancer. Biologic features can also vary by sex; several biomarkers with either prognostic or predictive value (ie, excisionrepair cross-complementation group 1 expression, epidermal growth factor receptor mutation, or dihydropyrimidine dehydrogenase polymorphism) may differentiate efficacy or toxicity in males and females. Taken together, age, sex, and comorbidity each encompass a complex array of physiologic and molecular variations that may each aid in personalizing care for the patient with cancer.

PubMed Disclaimer

Similar articles

• [Chemotherapy in the elderly: how and for whom?].
  Avenin D, Selle F, Gligorov J, Japkowicz M, Houssel P, Carette B, Bernard M, Abbas F, Khalil A, Bourayou N, Lokiec F, Carola E, Saint-Jean O, Leblond V, Bouvard E, Lotz JP. Avenin D, et al. Bull Cancer. 2008 May 28;95 FMC Onco:F28-36. doi: 10.1684/bdc.2007.0537. Bull Cancer. 2008. PMID: 18511364 French.
• Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
  Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD; National Cancer Institute of Canada Clinical Trials Group. Asmis TR, et al. J Clin Oncol. 2008 Jan 1;26(1):54-9. doi: 10.1200/JCO.2007.12.8322. J Clin Oncol. 2008. PMID: 18165640 Clinical Trial.
• NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
  National Toxicology Program. National Toxicology Program. Natl Toxicol Program Tech Rep Ser. 1993 Sep;422:1-340. Natl Toxicol Program Tech Rep Ser. 1993. PMID: 12616289
• Evaluating the older patient with cancer: understanding frailty and the geriatric assessment.
  Pal SK, Katheria V, Hurria A. Pal SK, et al. CA Cancer J Clin. 2010 Mar-Apr;60(2):120-32. doi: 10.3322/caac.20059. Epub 2010 Feb 19. CA Cancer J Clin. 2010. PMID: 20173172 Review.
• The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer.
  Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S. Hall WH, et al. Prostate Cancer Prostatic Dis. 2005;8(1):22-30. doi: 10.1038/sj.pcan.4500772. Prostate Cancer Prostatic Dis. 2005. PMID: 15700051 Review.

Cited by

• Incidence and Mortality due to Colorectal Cancer in Mongolia, 2018-2022.
  Tsedendorj Y, Zorigtbaatar S, Davaasuren NE, Dondov G, Ganbat T, Lonjid T, Batsaikhan A, Tudev U, Batsaikhan B. Tsedendorj Y, et al. Asian Pac J Cancer Prev. 2024 Jul 1;25(7):2305-2310. doi: 10.31557/APJCP.2024.25.7.2305. Asian Pac J Cancer Prev. 2024. PMID: 39068562 Free PMC article.
• Chemotherapy Toxicity in Older Adults Optimized by Geriatric Assessment and Intervention: A Non-Comparative Analysis.
  Hamid M, Hannan M, Myo Oo N, Lynch P, Walsh DJ, Matthews T, Madden S, O'Connor M, Calvert P, Horgan AM. Hamid M, et al. Curr Oncol. 2022 Aug 26;29(9):6167-6176. doi: 10.3390/curroncol29090484. Curr Oncol. 2022. PMID: 36135053 Free PMC article.
• Association between Socioeconomic Status and One-Month Mortality after Surgery in 20 Primary Solid Tumors: a Pan-Cancer Analysis.
  Sun W, Zhou H, Cheng M, Zhuang S, Qiu Z. Sun W, et al. J Cancer. 2020 Jul 11;11(18):5449-5455. doi: 10.7150/jca.46088. eCollection 2020. J Cancer. 2020. PMID: 32742492 Free PMC article.
• Research priorities in geriatric oncology for 2013 and beyond.
  Mohile S, Dale W, Magnuson A, Kamath N, Hurria A. Mohile S, et al. Cancer Forum. 2013 Nov;37(3):216-221. Cancer Forum. 2013. PMID: 25346565 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program